Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma

Melanoma Research
Panagiotis T DiamantopoulosHelen Gogas

Abstract

Ophthalmological complications constitute a class effect of treatment with BRAF inhibitors. Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib. In this study, we present a case of severe bilateral panuveitis and neurosensory hearing loss in an elderly patient treated with encorafenib and binimetinib for metastatic BRAF-mutant melanoma. This constellation of findings is compatible with incomplete Vogt-Koyanagi-Harada (VKH) disease. VKH disease is a rare multisystem disease characterized by granulomatous panuveitis, serous retinal detachments, and neurologic and dermatologic manifestations. In patients with melanoma, its emergence has been correlated to a favorable prognosis of the underlying melanoma by several authors. The patient reported here had a severe panuveitis and bilateral retinal detachments causing permanent visual impairment. She was treated with a long course of systemic corticosteroids, but at the same time, she achieved complete remission of the melanoma lasting for 26 months after permanent encorafenib and binimetinib discontinuation, without further antineoplastic treatment....Continue Reading

References

Mar 1, 1978·Archives of Dermatology·A J Sober, H A Haynes
Nov 1, 1996·The British Journal of Ophthalmology·K Norose, A Yano
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Nov 18, 2003·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Sabine AisenbreyRichard Brunner
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongRichard F Kefford
Jul 19, 2014·American Journal of Ophthalmology·Christina H ChoeRavi K Amaravadi
Oct 14, 2017·CA: a Cancer Journal for Clinicians·Jeffrey E GershenwaldUNKNOWN for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Disc

❮ Previous
Next ❯

Citations

Oct 2, 2020·European Journal of Ophthalmology·Maria BrambatiElisabetta Miserocchi
Dec 30, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Florentia DimitriouMartin Urner
Apr 1, 2021·Drugs·Blake H FortesLauren A Dalvin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.